Microbiome Test for the Detection of Colorectal Polyps

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

600 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-27

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main goal of this trial is to validate a new method for colorectal polyp screening based on stool microbiome signatures. 600 Individuals who are scheduled / planned to undergo a colonoscopy will be recruited for this study and a stool sample and an optional saliva sample will be collected.

Analyze process will be conducted on the microbiome of the samples given.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Microbiome Test for the Detection of Colorectal Polyps and Cancer

NCT02141945

Colorectal Neoplasms Colorectal Cancer

COMPLETED

Colonoscopy vs Stool Testing for Older Adults With Colon Polyps

NCT05612347

Colorectal Polyp Colorectal Neoplasms Colorectal Adenoma +2 more

RECRUITING NA

Stool Sample Collection Study

NCT06294873

Colorectal Cancer

RECRUITING

Screening for Stomach Diseases and Colorectal Neoplasms With the Fecal Testing

NCT01741363

Colorectal Cancer Stomach Disease

COMPLETED NA

Development and Validation of Microbiota and Metabolite-based Prediction Model for Recurrence of High-risk Colorectal Polyps After Polypectomy

NCT06957626

Colorectal Polyp Colorectal Cancer Recurrent Colorectal Adenoma

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Colorectal cancer (CRC) is the second cause of cancer death in the US. The pathogenesis of CRC is complex, involving a progressive transition of the healthy colonic mucosa to pre-cancerous polyps, and eventually to CRC. One of the factors that are proposed to cause this 'adenoma-carcinoma sequence' is the dysbiosis of the gut microbiome.

The gut microbiota has been identified as a potential screening biomarker for CRC, since studies have reported specific bacterial taxa and/ or microbial signatures as important factors in the etiology of CRC.

Hypothesis:

comprehensive and cutting-edge metagenomic analysis of the fecal microbiome of individuals with colonic polyps vs. patients without polyps will identify microbial signatures associated with colonic polyps and will define these microbial signatures as biomarkers and risk factors for CRC.

method:

* Collect data (anthropometric, demographic, dietary, lifestyle habits, medical and family history) and stool \& optional Saliva sample for microbiome analysis from a cohort of 600 colonoscopies screened individuals.
* Analyze this data with an aim to utilize advanced artificial intelligence and machine-learning techniques to classified microbiome signatures, which are correlated to colonoscopy (and to histological) results.
* Blinded Validation - A sub-cohort of 300 individuals (who are part of the 600 individuals) that were not used to classify the biomarkers signatures will be used to validate the diagnosis model.

Data analysis:

The stool and optional Saliva samples will be sent to metagenomic sequencing, thereby generating FASTQ libraries of the reads found in the stool \& saliva samples. These files will be analyzed by the BiotaX diagnostics platform.

No Human DNA analysis will take place at this clinical study. Only a microbial analysis will take place.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colon Polyp

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

colonoscopy

Participants will be patients undergoing colonoscopy

Group Type EXPERIMENTAL

biotax

Intervention Type DIAGNOSTIC_TEST

patients who are scheduled to undergo colonoscopy will be asked to participate and give a stool sample

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

biotax

patients who are scheduled to undergo colonoscopy will be asked to participate and give a stool sample

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males or females.
2. Age: 45-70 years, inclusive.
3. Patients without any incapacitating systemic disease
4. Able to comprehend and provide informed consent.
5. Patients who are scheduled / planned to undergo a colonoscopy, preferably: participants who are undergoing a colonoscopy as a diagnostic surveillance.

Exclusion Criteria

1. Subject has a history of colorectal cancer (CRC)
2. Subject has a diagnosis or medical history of any of the following conditions:

* Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP and Gardner's syndrome)
* Hereditary non-polyposis CRC syndrome (also referred to as "HNPCC" or "Lynch Syndrome")
3. Subject has a diagnosis or personal history of inflammatory bowel disease (IBD), including chronic ulcerative colitis or Crohn's disease.
4. Patients with incapacitating systemic disease
5. Any use of antibiotics within one months prior to colonoscopy.

Minimum Eligible Age

45 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No